SCHEMBL10125840

SCHEMBL10125840

Cc1cc(-c2nc3ccccc3nc2-c2ccccc2)c(C)cc1-c1ccc(-c2nc3ccccc3o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.51
RAB9A P51151 7/20 0.51
KDM4E B2RXH2 6/20 0.51
HPGD P15428 6/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
CASP3 P42574 2/20 0.51
SENP8 Q96LD8 2/20 0.51
SENP7 Q9BQF6 2/20 0.51
SENP6 Q9GZR1 2/20 0.51
POLB P06746 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 3/20 0.49
USP2 O75604 2/20 0.49
HCRTR1 O43613 2/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126020 0.95 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125821 0.92 KDM4E (0.53) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10126006 0.89 KDM4E (0.52) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125839 0.87 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10315239 0.85 NPC1 (0.43) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL12721754 0.85 NPC1 (0.51) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125899 0.85 NPC1 (0.54) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125807 0.85 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL23606298 0.85 NPC1 (0.63) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125829 0.85 NPC1 (0.63) NPC1RAB9AKDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885KDM4E 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.